Merelbeke, 12th of November 2021
Belgian based Ceres Pharma, a dynamic and fast growing pharmaceutical company, active in healthcare & well-being, has completed the acquisition of GlobiFer Intl.
The acquisition of GlobiFer Intl. fits perfectly within Ceres Pharma’s women’s health strategy and is an important step to exploit Ceres Pharma’s export potential.
GlobiFer® is a natural food supplement with a unique iron formulation to quickly and efficiently correct iron deficiency and to help maintain the hemoglobin level. GlobiFer® is on the market since 2013. The original concept was developed in the early 80’s by a Swedish hematologist at the Karonlinska Hospital in Stockholm. Currently the GlobiFer® products are available in 35 countries.
"I am very happy that we have come to an agreement with GlobiFer Intl. This acquisition fits perfectly within Ceres Pharma’s women’s health strategy. The GlobiFer® branded products are complementary with our actual woman’s health product portfolio and the GlobiFer network of renowned distributor partners in more than 35 countries, is an important step to exploit Ceres Pharma’s export potential”, says Mario Debel, CEO of Ceres Pharma.
GlobiFer Intl. realized a turnover of 4 million euros in 2020. Anthony Popowski, Managing Partner at GlobiFer Intl., will remain on board. The price of the takeover will not be disclosed. “I am pleased to be part of a strong, dynamic and fast growing international group, such as Ceres Pharma. Together, we will be stronger to execute our ambitious growth plan and we will be able to sell Ceres Pharma brands to new and existing customers", says Anthony Popowski, Managing Partner at GlobiFer Intl.
About GlobiFer Intl.
Belgian based GlobiFer Intl. is with their GlobiFer® brand a strong international player - present in more than 35 countries - in natural food supplements with a unique iron formulation, to quickly and efficiently correct iron deficiency and to help maintain the hemoglobin level.
About Ceres Pharma
Ceres Pharma is a dynamic and fast growing, Belgian based, pharmaceutical company, founded in 2017 by CEO Mario Debel and Alychlo and recently acquired by Naxicap Partners. It is the ambition of Ceres Pharma to grow through the development of its own product portfolio as well as through acquisitions. Ceres Pharma is active in the development and distribution of drugs, medical devices, biocides, cosmetics, qualitative food supplements and pharmaceutical preparations in the Benelux and in Central and Eastern Europe.
About Naxicap Partners
As one of the top private equity firms in France, Naxicap Partners - an affiliate of Natixis Investment Managers - has €3.7 billion in assets under management. As a committed, responsible investor, Naxicap Partners builds solid, constructive partnerships with entrepreneurs so that their projects can succeed. The firm has 39 investment professionals spread across five offices in Paris, Lyon, Toulouse, Nantes and Frankfurt.